Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Plerixafor ‘just in time’ for stem cell mobilization in a normal donor

Bone Marrow Transplantation volume 46, pages 1026–1027 (2011)Cite this article

Subjects

Plerixafor can be used to mobilize successfully autologous stem cells in patients who have failed traditional mobilization techniques.1 It has also been used in pilot studies in normal donors to mobilize sufficient stem cells to allow transplantation.2 We recently used it in a normal donor who failed to mobilize adequate numbers of stem cells with G-CSF.

A 56-year-old woman was identified as a normal donor for her HLA-matched sibling. Her history was unremarkable except for controlled depression and anxiety. Baseline blood count was normal: WBC 6.1 × 109 per liter, Hb 12.8 g per 100 mL and platelets 195 × 109 per liter. PTT was elevated and an incidental diagnosis of a lupus anticoagulant was carried out. Her weight was 42 kg and the recipient weighed 75 kg.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K et al. AMD 3100 plus G-CSF can successfully mobilize CD34+ cells from non Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma previously failing mobilization with chemotherapy and/or cytokine treatment. Bone Marrow Transplant 2008; 41: 330–338.

    Article  Google Scholar 

  2. Devine S, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112: 990–998.

    Article  CAS  Google Scholar 

  3. Wang TF, Wen SH, Chen RL, Lu CJ, Zheng YJ, Yang SH et al. Factors associated with peripheral blood stem cell yield in volunteer donors mobilized with granulocyte colony-stimulating factors: the impact of donor characteristics and procedural settings. Biol Blood Marrow Transplant 2008; 14: 1305–1311.

    Article  Google Scholar 

  4. Anderlini P, Przepiorka D, Seong C, Smith T, Huh Y, Lauppe J et al. Factors affecting mobilization of CD341 cells in normal donors treated with filgrastim. Transfusion 1997; 37: 507–512.

    Article  CAS  Google Scholar 

  5. Vasu S, Leitman SF, Tisdale JF, Hsieh M, Childs R, Barrett J et al. Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood 2008; 112: 2092–2100.

    Article  CAS  Google Scholar 

  6. Ings SJ, Balsa C, Leverett D, Mackinnon S, Linch D, Watt M . Peripheral blood stem cell yield in 400 normal donors mobilized with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol 2006; 134: 517–525.

    Article  Google Scholar 

  7. Richa E, Papari M, Allen J, Marinez G, WIckrema A, Anastasi J et al. Older age but not donor health impairs allogeneic granulocyte colony stimulating factor (G-CSF) peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 2009; 15: 1394–1399.

    Article  CAS  Google Scholar 

  8. DiPersio JF, Micallef IN, Stiff PJ, Bolwell B, Maziarz R, Jacobsen E et al. Phase 3 prospective randomized double-blind placebo-controlled trial of plerixafor plus G-CSF versus placebo plus G-CSF for autologous stem cell mobilization and transplantation in patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767–4773.

    Article  CAS  Google Scholar 

  9. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720–5726.

    CAS  PubMed  Google Scholar 

  10. Leotta S, Poidomani M, Maura E, Spadaro A, Marturano E, Milone G . AMD 3100 for urgent PBSC mobilization and allogeneic transplantation from a normal donor alter failed marrow harvest. Bone Marrow Transplant 2011; 46: 314–316.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. City of Hope Banner BMT Program, Phoenix, AZ, USA

    J Schriber, V Fauble, L O Sproat & A Briggs

Authors
  1. J Schriber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V Fauble
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L O Sproat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Briggs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Schriber.

Ethics declarations

Competing interests

JS is on the Speaker's Bureau for Genzyme that produces plerixafor. The authors declare no sources of support.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schriber, J., Fauble, V., Sproat, L. et al. Plerixafor ‘just in time’ for stem cell mobilization in a normal donor. Bone Marrow Transplant 46, 1026–1027 (2011). https://doi.org/10.1038/bmt.2010.226

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.226

Search

Advanced search

Quick links